Viome Life Sciences has launched CancerDetect Pancreatic, a physician-ordered blood test designed to detect pancreatic ductal adenocarcinoma by measuring enzyme activity associated with the disease. In the company’s blinded validation, the test detected stage I and II pancreatic cancers with 86% sensitivity and 90% specificity against healthy controls. Unlike tests that rely on detecting tumor DNA, the technology measures enzymes involved in the breakdown of surrounding tissue, using signal amplification to detect very low concentrations. The test is intended for adults aged 50 and older, with particular interest in people at elevated risk, including those with certain genetic mutations, a…
Author: Abhay Panchal
Researchers at the University of Tokyo have developed a prototype ingestible capsule designed to collect biological samples from hard-to-reach regions of the small intestine. Published in Device, the study describes a pill-shaped device containing a retractable brush that is controlled by external magnets. In laboratory experiments using extracted pig intestines, two robotic arms equipped with magnets controlled the capsule’s position and operated its internal mechanism. The brush extended to sweep samples from the intestinal surface before retracting into the capsule. The collected material was suitable for 16S rRNA gene sequencing, a method commonly used to analyze microbial communities. Unlike conventional…
A new feature by Prateek Sharma, MD, and Jillian Mock examines two developments in endoscopy: successful repeat colonoscopy after an incomplete examination and the creation of a structured video databank for AI research. Repeat colonoscopy: A 24-year retrospective study of 1,334 patients at Indiana University found that repeat colonoscopy achieved 96.1% cecal intubation overall after an unsuccessful initial examination. Success rates were 97.0% for difficult sigmoid colons and 96.9% for redundant colons. Of 31 lesions measuring at least 20 mm detected during repeat colonoscopy, 20 had not been identified in prior radiographic studies. The findings support referral to experienced endoscopists…
Gastroenterology’s growing reliance on anesthesia-supported sedation is emerging as a constraint on endoscopy capacity, particularly in rural areas where workforce shortages have forced some ambulatory surgery centers (ASCs) and endoscopy centers to close for the day. According to Amy Oxentenko, MD, vice dean of practice and chief patient experience officer at Mayo Clinic, the dependency developed as procedures became more complex and patients presented with greater sedation-related risks. However, anesthesia support has increasingly become routine, even when moderate sedation administered by gastroenterologists may be appropriate.
In this clinical perspective, David A. Schwartz, MD, discusses evolving treatment strategies for perianal fistulizing Crohn’s disease, emphasizing early advanced therapy and coordinated medical-surgical management. Anti-TNF agents, particularly infliximab, remain the best-established treatment option. The American Gastroenterological Association’s broader guidance supporting earlier advanced therapy in moderate-to-severe Crohn’s disease reinforces the need to avoid prolonged ineffective conventional treatment, although it does not introduce new fistula-specific recommendations. For active fistulas without an abscess, combining a biologic with an antibiotic is recommended for induction of remission.
A retrospective analysis presented at the 2026 ASCO Breakthrough Meeting found that GLP-1 receptor agonist use was associated with a lower five-year incidence of colorectal cancer (CRC) among patients with inflammatory bowel disease (IBD), including those with coexisting type 2 diabetes. Led by Sarina Ailawadi, DO, of Case Western Reserve University and University Hospitals, the study used the TriNetX US healthcare database and propensity score matching to compare patients receiving GLP-1 therapies with matched nonusers. In the matched IBD cohort, five-year CRC incidence was 0.20% among GLP-1 users versus 0.43% among nonusers, corresponding to 51% lower odds. Among patients with…
A study published in The Journal of Molecular Diagnostics found that Haystack MRD, an ultrasensitive circulating tumor DNA (ctDNA) liquid biopsy test from Quest Diagnostics, accurately detected residual or recurrent colorectal cancer in an analysis of patient specimens from the DYNAMIC and DYNAMIC-III clinical trials. These trials investigated ctDNA-guided adjuvant chemotherapy decisions in stage II and stage III colorectal cancer. At three-year follow-up, the assay demonstrated 100% sensitivity and 100% specificity; at five years, sensitivity was 83.3%, with specificity remaining at 100%. Over a median follow-up of 60 months, the test also outperformed carcinoembryonic antigen (CEA), detecting recurrence with 88.9%…
A post hoc analysis of the prospective REVEAL study suggests that preoperative gut microbiome composition may contain prognostic information for patients with early-stage colorectal cancer. The study included 204 patients with stage I–III CRC, with an overall recurrence rate of 21%, and analyzed fecal samples using 16S rRNA gene sequencing. Patients who subsequently developed locoregional recurrence had different microbial profiles from those who did not. In particular, higher preoperative abundance of Porphyromonas was associated with a greater risk of recurrence, with a reported hazard ratio of 2.80. Several other bacterial genera were associated with locoregional or distant recurrence, although Porphyromonas…
A U.S. survey of 351 gastroenterologists, GI fellows and surgeons, presented at DDW 2026, found that while most respondents support performing a second inspection of the right colon during colonoscopy, the practice is not consistently incorporated into institutional policy or quality measurement. Prior evidence suggests a second right-colon inspection can increase adenoma detection by about 7%, and AGA and ACG/ASGE recommendations already support a second view using either retroflexion or forward viewing. However, the societies do not currently specify how the practice should be incorporated into quality metrics. In the survey, 81% of respondents believed second inspection increases ADR and…
A new CDOTrends analysis examines the gap between the growing number of AI-enabled medical devices and the much smaller body of evidence demonstrating that these tools improve patient outcomes. The article cites FDA data showing 1,524 authorized AI-enabled medical devices as of March 2026, with 76% in radiology. It also references a PLOS Digital Health analysis finding that only 34 of 1,357 FDA-cleared AI devices reviewed had links to registered clinical trials, and only three had been evaluated using patient-centered outcomes. The article uses gastroenterology as a particularly relevant example. Mark Lambrecht of SAS describes a gastroenterologist who keeps AI…
